Mode
Text Size
Log in / Sign up

POCUS-guided assessments and serial exchange transfusions improved outcomes in a 20-year-old male with sickle cell disease and acute chest syndromeBedside Ultrasound Saves Sickle Cell Lives

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider using POCUS to monitor hemodynamics and guide exchange transfusions when immediate HbS quantification is delayed in sickle cell crises.

This case report details the management of a 20-year-old male patient with HbSS presenting with acute chest syndrome and acute pulmonary hypertension in an ICU setting. The intervention involved POCUS-guided assessments of pulmonary arterial pressures via tricuspid regurgitation jet velocities alongside serial exchange transfusions. This approach was utilized because delayed access to hemoglobin electrophoresis hindered real-time monitoring of HbS percentages.

Main results indicated that the first exchange transfusion reduced HbS to 49%. Following a second exchange transfusion, the patient achieved a therapeutic HbS level of 20.9%. Prior to these interventions, a tricuspid regurgitation jet velocity (TRV) of 3.74 m/s placed the patient in a high-mortality cohort with a P value of less than 0.001. After the second procedure, tachycardia, dyspnea, and oxygen requirements rapidly improved. The diagnostic accuracy of POCUS was reported as high, with an AUC of 0.87.

Regarding safety and tolerability, the report notes that adverse events, serious adverse events, discontinuations, and specific tolerability data were not reported. The patient did not experience right heart failure or mortality during the described course. However, the study design is limited by its nature as a single case report.

The practice relevance suggests that POCUS may be utilized as a real-time hemodynamic monitor to guide the necessity of serial exchange transfusions in the absence of immediate HbS% quantification. Clinicians should interpret these findings cautiously given the lack of a control group and the single-patient sample size.

Sickle cell disease affects millions of people worldwide. For many, the most dangerous complication is called acute chest syndrome. This happens when the sickle cells clog the lungs, causing fever, coughing, and rapid breathing problems. If untreated, it can lead to heart failure and death.

Doctors usually watch for lab numbers to decide when to give more blood. But what if those numbers are not ready yet? What if the patient's condition worsens while the lab is still working? In these moments, every minute counts. The heart has to work harder to pump blood through clogged vessels. High pressure builds up in the lungs, putting a massive strain on the right side of the heart.

The Surprising Shift

For years, doctors waited for the lab report before acting. They assumed the patient was stable until the numbers came back. But this waiting game is dangerous. A patient can slip into a crisis before the results arrive.

But here is the twist. Doctors now have a powerful tool right at the patient's side. A portable ultrasound machine can measure blood pressure in the heart instantly. It does not wait for a lab. It gives an immediate answer about the patient's safety.

What Scientists Didn't Expect

To understand this, think of your heart as a pump and your blood vessels as a garden hose. When the hose is kinked or blocked, the pump has to push much harder. This creates high pressure. In sickle cell disease, the sickle cells act like kinks in the hose.

The ultrasound looks at a specific valve in the heart called the tricuspid valve. When blood flows backward through this valve, it creates a jet of water. The speed of this jet tells the doctor the pressure in the heart. A fast jet means high pressure. High pressure means the heart is struggling.

This is like checking the water pressure in a hose with your finger instead of waiting for a gauge to be mailed to you. It is fast, direct, and tells you exactly what is happening inside the body right now.

The Case Study

The story comes from a 20-year-old man with severe sickle cell disease. He arrived at the hospital with severe pain and trouble breathing. His blood count showed he was losing red blood cells quickly. Doctors gave him an exchange transfusion, which swaps out the bad blood for good blood.

However, his breathing got worse. He needed more oxygen. The lab results were still coming. The ultrasound showed a very fast jet coming from his heart valve. This meant his heart pressure was dangerously high. The doctors knew he was in a high-risk group.

The Critical Finding

After the second transfusion, the ultrasound changed. The jet became much slower. The pressure dropped. His breathing improved rapidly. The lab results later confirmed that the second transfusion worked much better than the first.

The key lesson is clear. The ultrasound detected the danger before the lab results were ready. It told the doctors exactly when to act. Without this tool, the patient might have waited too long. Waiting too long in these cases can lead to permanent heart damage or death.

This doesn't mean this treatment is available yet.

It is important to remember that this is a new method being tested. It is not a magic cure, but a smarter way to monitor patients. It helps doctors make better decisions when they are under pressure.

If you or a loved one has sickle cell disease, this news is hopeful. It means doctors have better tools to keep you safe. It means you will not have to wait as long for answers.

If you are a caregiver, know that doctors are using new technology to watch your loved ones more closely. If you are a patient, talk to your doctor about how they monitor your heart pressure. Ask if they use ultrasound to check on your lung and heart health during a crisis.

The Limitations

This study focused on one specific case. While the results were very promising, we need to see if this works for many patients. The study was small. It involved only one person. We need more data to be sure this works for everyone. Also, not every hospital has this specific ultrasound equipment ready for this purpose.

The next step is to test this method with many more patients. Researchers want to see if this approach saves lives in real hospitals across the country. If it works well, it could become a standard part of sickle cell care.

This change could happen soon. It turns a waiting game into an active strategy. Doctors can act fast when the heart needs help. For patients with sickle cell disease, this is a step toward safer, faster, and more effective care.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Acute chest syndrome (ACS) is a leading cause of mortality in Sickle Cell Disease (SCD), often characterized by rapid respiratory decline and acute pulmonary hypertension (PH). While exchange transfusion is the standard of care for severe cases, delayed access to hemoglobin (Hb) electrophoresis often hinders real-time monitoring of therapeutic efficacy. We propose that POCUS guided assessments of pulmonary arterial pressures via tricuspid regurgitation jet velocities can serve as a real-time hemodynamic tool to direct serial exchange transfusions thereby preventing right heart failure and mortality in severe acute chest syndrome. A 20-year-old male patient with HbSS (baseline HbS 28.7%, on hydroxyurea) presented with shortness of breath, severe hip/back pain and acute hemolysis (Hb 8.3 g/dL, bilirubin 7.4 mg/dL, LDH 484 U/L). Despite treatment for ACS and an initial exchange transfusion, his oxygen requirements escalated from simple nasal cannula to high-flow nasal cannula. Repeated imaging showed worsening infiltrates, and Point-of-Care Ultrasound (POCUS) revealed acute PH (TR jet velocity > 4 m/s). Following the second exchange transfusion, the patient’s tachycardia, dyspnea, and oxygen requirements rapidly improved. Follow-up Point-of-Care Ultrasound (POCUS) demonstrated an improved and now trace tricuspid regurgitation. Subsequent electrophoresis confirmed the first exchange only reduced HbS to 49%, while the second achieved a therapeutic level of 20.9% (recommended target HbS of This case demonstrates that acute elevations in pulmonary artery pressure can serve as a critical surrogate marker for ongoing sickling when electrophoresis results are delayed. The patient’s TRV of 3.74 m/s placed him in a high-mortality cohort (P < 0.001). Given that POCUS provides high diagnostic accuracy (AUC 0.87), it may be utilized as a real-time hemodynamic monitor to guide the necessity of serial exchange transfusions in the absence of immediate HbS% quantification. In severe ACS, achieving a target HbS ≤ 30% is vital, and bedside echocardiography may identify patients requiring immediate repeat exchange transfusion to prevent right heart failure and death.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.